{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:22:34Z","timestamp":1765545754866},"reference-count":54,"publisher":"Japan Atherosclerosis Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT"],"published-print":{"date-parts":[[2012]]},"DOI":"10.5551\/jat.11601","type":"journal-article","created":{"date-parts":[[2012,4,4]],"date-time":"2012-04-04T03:55:45Z","timestamp":1333511745000},"page":"559-569","source":"Crossref","is-referenced-by-count":25,"title":["Effects of PPIs and an H2 blocker on the Antiplatelet Function of Clopidogrel in Japanese Patients under Dual Antiplatelet Therapy"],"prefix":"10.5551","volume":"19","author":[{"given":"Keiichiro","family":"Yamane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Tazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohisa","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeru","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Jinnai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryutaro","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisanori","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.17.2126"},{"key":"2","unstructured":"1) Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Car-lino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A: Incidence, predictors, and out-come of thrombosis after successful implantation of drug-eluting stents. JAMA, 2005; 293: 2126-2130"},{"key":"3","doi-asserted-by":"crossref","unstructured":"2) Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Wil-liams DO, Pocock SJ, Kuntz RE: A clinical trial compar-ing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. N Engl J Med, 1998; 339: 1665-1671","DOI":"10.1056\/NEJM199812033392303"},{"key":"4","doi-asserted-by":"crossref","unstructured":"3) Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA: Effects of pretreat-ment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet, 2001; 358: 527-533","DOI":"10.1016\/S0140-6736(01)05701-4"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05701-4"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-869523"},{"key":"7","doi-asserted-by":"crossref","unstructured":"4) Savi P, Herbert JM: Clopidogrel and ticlopidine: P2y12 adenosine diphosphate-receptor antagonists for the pre-vention of atherothrombosis. Semin Thromb Hemost, 2005; 31: 174-183","DOI":"10.1055\/s-2005-869523"},{"key":"8","doi-asserted-by":"crossref","unstructured":"5) Horiuchi H: Recent advance in antiplatelet therapy: The mechanisms, evidence and approach to the problems. Ann Med, 2006; 38: 162-172","DOI":"10.1080\/07853890600640657"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1080\/07853890600640657"},{"key":"10","doi-asserted-by":"crossref","unstructured":"6) Ueno M, Kodali M, Tello-Montoliu A, Angiolillo DJ: Role of platelets and antiplatelet therapy in cardiovascular disease. J Atheroscler Thromb, 2011; 18: 431-442","DOI":"10.5551\/jat.7633"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.5551\/jat.7633"},{"key":"12","doi-asserted-by":"crossref","unstructured":"7) Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Fara-day N, Herzog W, Gurbel PA: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clin-ical efficacy of clopidogrel therapy. JAMA, 2009; 302: 849-857","DOI":"10.1001\/jama.2009.1232"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1232"},{"key":"14","doi-asserted-by":"crossref","unstructured":"8) Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braun-wald E, Sabatine MS: Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med, 2009; 360: 354-362","DOI":"10.1056\/NEJMoa0809171"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809171"},{"key":"16","doi-asserted-by":"crossref","unstructured":"9) Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M, Ono K, Hoshino K, Naruse Y, Takahashi K, Watanabe H, Kita T, Kimura T: Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in japan. Circ J, 2009; 73: 1498-1503","DOI":"10.1253\/circj.CJ-09-0019"},{"key":"17","doi-asserted-by":"crossref","unstructured":"9) Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M, Ono K, Hoshino K, Naruse Y, Takahashi K, Watanabe H, Kita T, Kimura T: Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in japan. Circ J, 2009; 73: 1498-1503","DOI":"10.1253\/circj.CJ-09-0019"},{"key":"18","doi-asserted-by":"crossref","unstructured":"10) Umemura K, Furuta T, Kondo K: The common gene variants of CYP2C19 affect pharmacokinetics and phar-macodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost, 2008; 6: 1439-1441","DOI":"10.1111\/j.1538-7836.2008.03050.x"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03050.x"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1007\/BF00316090"},{"key":"21","doi-asserted-by":"crossref","unstructured":"11) Alvan G, Bechtel P, Iselius L, Gundert-Remy U: Hydrox-ylation polymorphisms of debrisoquine and mephenytoin in european populations. Eur J Clin Pharmacol, 1990; 39: 533-537","DOI":"10.1007\/BF00316090"},{"key":"22","doi-asserted-by":"crossref","unstructured":"12) Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BI, Liao CL, Zhang LM: Metoprolol and mephe-nytoin oxidation polymorphisms in far eastern oriental subjects: Japanese versus mainland chinese. Clin Pharma-col Ther, 1989; 46: 198-207","DOI":"10.1038\/clpt.1989.126"},{"key":"23","doi-asserted-by":"crossref","unstructured":"13) Kang MK, Jeong YH, Yoon SE, Koh JS, Kim IS, Park Y, Hwang SJ, Kwak CH, Hwang JY: Pre-procedural platelet reactivity after clopidogrel loading in korean patients undergoing scheduled percutaneous coronary interven-tion. J Atheroscler Thromb, 2010; 17: 1122-1131","DOI":"10.5551\/jat.4564"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.5551\/jat.4564"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.191087"},{"key":"26","doi-asserted-by":"crossref","unstructured":"14) Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM: ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet ther-apy and nsaid use: A report of the american college of car-diology foundation task force on clinical expert consensus documents. Circulation, 2008; 118: 1894-1909","DOI":"10.1161\/CIRCULATIONAHA.108.191087"},{"key":"27","doi-asserted-by":"crossref","unstructured":"15) Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Compari-son of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantopra-zole, and rabeprazole on human cytochrome p450 activi-ties. Drug Metab Dispos, 2004; 32: 821-827","DOI":"10.1124\/dmd.32.8.821"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.8.821"},{"key":"29","doi-asserted-by":"crossref","unstructured":"16) Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G, Mansourati J, Mottier D, Abgrall JF, Boschat J: Influence of omeprazole on the antiplatelet action of clop-idogrel associated with aspirin: The randomized, double-blind OCLA (omeprazole clopidogrel aspirin) study. J Am Coll Cardiol, 2008; 51: 256-260","DOI":"10.1016\/j.jacc.2007.06.064"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.06.064"},{"key":"31","doi-asserted-by":"crossref","unstructured":"17) Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peter-son ED, Rumsfeld JS: Risk of adverse outcomes associ-ated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA, 2009; 301: 937-944","DOI":"10.1001\/jama.2009.261"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.261"},{"key":"33","doi-asserted-by":"crossref","unstructured":"18) Aubert RE, Epstein RS, Teagarden JR, Xia F, Yao J, Desta Z, Skaar T, Flockhart DA: Proton pump inhibitors effect on clopidogrel effectiveness: The clopidogrel medco out-comes study. Circulation, 2008; 118: S815","DOI":"10.1161\/circ.118.suppl_18.S_815"},{"key":"34","doi-asserted-by":"crossref","unstructured":"18) Aubert RE, Epstein RS, Teagarden JR, Xia F, Yao J, Desta Z, Skaar T, Flockhart DA: Proton pump inhibitors effect on clopidogrel effectiveness: The clopidogrel medco out-comes study. Circulation, 2008; 118: S815","DOI":"10.1161\/circ.118.suppl_18.S_815"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e318202f701"},{"key":"36","doi-asserted-by":"crossref","unstructured":"19) Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF: ACCF\/ACG\/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of anti-platelet therapy and nsaid use: A report of the american college of cardiology foundation task force on expert con-sensus documents. Circulation, 2010; 122: 2619-2633","DOI":"10.1161\/CIR.0b013e318202f701"},{"key":"37","doi-asserted-by":"crossref","unstructured":"20) Taha AS, McCloskey C, Prasad R, Bezlyak V: Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): A phase iii, randomised, double-blind, placebo-controlled trial. Lan-cet, 2009; 374: 119-125","DOI":"10.1016\/S0140-6736(09)61246-0"},{"key":"38","doi-asserted-by":"crossref","unstructured":"21) Ng FH, Wong SY, Lam KF, Chu WM, Chan P, Ling YH, Kng C, Yuen WC, Lau YK, Kwan A, Wong BC: Famoti-dine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterol-ogy, 2010; 138: 82-88","DOI":"10.1053\/j.gastro.2009.09.063"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.09.063"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.808311"},{"key":"41","doi-asserted-by":"crossref","unstructured":"22) Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, Nishikawa H, Hiasa Y, Muramatsu T, Meguro T, Inoue N, Honda H, Hayashi Y, Miyazaki S, Oshima S, Honda T, Shiode N, Namura M, Sone T, Nobuyoshi M, Kita T, Mitsudo K: Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implan-tation. Circulation, 2009; 119: 987-995","DOI":"10.1161\/CIRCULATIONAHA.108.808311"},{"key":"42","doi-asserted-by":"crossref","unstructured":"23) Born GV, Hume M: Effects of the numbers and sizes of platelet aggregates on the optical density of plasma. Nature, 1967; 215: 1027-1029","DOI":"10.1038\/2151027a0"},{"key":"43","doi-asserted-by":"crossref","unstructured":"24) Tabuchi A, Taniguchi R, Takahashi K, Kondo H, Kawato M, Morimoto T, Kimura T, Kita T, Horiuchi H: Action of aspirin on whole blood-aggregation evaluated by the screen filtration pressure method. Circ J, 2008; 72: 420-426","DOI":"10.1253\/circj.72.420"},{"key":"44","doi-asserted-by":"crossref","unstructured":"25) Hoshino K, Horiuchi H, Tada T, Tazaki J, Nishi E, Kawato M, Ikeda T, Yamamoto H, Akao M, Furukawa Y, Shizuta S, Toma M, Tamura T, Saito N, Doi T, Ozasa N, Jinnai T, Takahashi K, Watanabe H, Yoshikawa Y, Nishi-moto N, Ouchi C, Morimoto T, Kita T, Kimura T: Clopi-dogrel resistance in Japanese patients scheduled for per-cutaneous coronary intervention. Circ J, 2009; 73: 336-342","DOI":"10.1253\/circj.CJ-08-0559"},{"key":"45","doi-asserted-by":"crossref","unstructured":"26) Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Had-amitzky M, Schomig A, Kastrati A, von Beckerath N: Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost, 2009; 101: 714-719","DOI":"10.1160\/TH08-12-0808"},{"key":"46","doi-asserted-by":"crossref","unstructured":"26) Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Had-amitzky M, Schomig A, Kastrati A, von Beckerath N: Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost, 2009; 101: 714-719","DOI":"10.1160\/TH08-12-0808"},{"key":"47","doi-asserted-by":"crossref","unstructured":"27) Furuta T, Iwaki T, Umemura K: Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol, 2010; 70: 383-392","DOI":"10.1111\/j.1365-2125.2010.03717.x"},{"key":"48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03717.x"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.26.386"},{"key":"50","doi-asserted-by":"crossref","unstructured":"28) Kita T, Sakaeda T, Baba T, Aoyama N, Kakumoto M, Kurimoto Y, Kawahara Y, Okamura N, Kirita S, Kasuga M, Okumura K: Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull, 2003; 26: 386-390","DOI":"10.1248\/bpb.26.386"},{"key":"51","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61525-7"},{"key":"52","doi-asserted-by":"crossref","unstructured":"29) O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD: Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials. Lancet, 2009; 374: 989-997","DOI":"10.1016\/S0140-6736(09)61525-7"},{"key":"53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007964"},{"key":"54","doi-asserted-by":"crossref","unstructured":"30) Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP: Clopido-grel with or without omeprazole in coronary artery dis-ease. N Engl J Med, 2010; 363: 1909-1917","DOI":"10.1056\/NEJMoa1007964"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T04:19:08Z","timestamp":1641961148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/19\/6\/19_11601\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.11601","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}